Veraxa Biotech is trading 11.59% down now at $1.45 after falling from its August 26 close of $1.64, with no credible company-specific announcement or filing dated August 27, 2026 explaining the decline.
- The latest investor-relations release, dated August 24, described a positive research milestone with Secarna Pharmaceuticals rather than adverse news.
- Broader markets were higher, so no clear market-wide catalyst explains the drop.